At 5.7% CAGR, the Middle East & Africa Newborn Screening Market is Projected to be Worth US$ 45.24 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Middle East & Africa newborn screening market was valued at US$ 28.94 in 2022 and is expected to reach US$ 45.24 million by 2030, registering a CAGR of 5.7% from 2022 to 2030. Surging government funding for newborn screening and rising burden of congenital diseases are among the critical factors attributed to the Middle East & Africa newborn screening market expansion.

Governments of different countries are increasingly allocating funds for newborn screening programs. These programs help reduce long-term healthcare costs for children and their parents as congenital and genetic disorders could result in severe health complications and extensive medical interventions if left undetected. By identifying and addressing health issues in infancy, governments can enhance the health and well-being of their citizens. Thus, newborn screening aligns with broader public health objectives to improve overall population health and reduce the burden on healthcare systems.

Government funding promotes equity in healthcare access, ensuring that newborn screening services are available to all, regardless of socioeconomic status. This inclusivity is essential for early disease detection and intervention, as it prevents disparities in healthcare outcomes among different demographic groups. As governments continue to prioritize newborn screening through increased funding and policy support, the newborn screening market has been experiencing sustainable growth worldwide.

On the contrary, lack of uniformity in newborn screening policies and practices hampers the growth Middle East & Africa newborn screening market.

Based on product type, the Middle East & Africa newborn screening market is bifurcated into reagents and assay kits, and instruments. The reagents and assay kits segment held 71.9% share of the Middle East & Africa newborn screening market in 2022, amassing US$ 20.80 million. It is projected to garner US$ 34.64 million by 2030 to expand at 6.6% CAGR during 2022-2030. The reagents and assay kits segment is subsegmented into DNA-based assays, and immunoassays and enzymatic assays. Instruments segment is subsegmented into newborn disorder screening instruments, pulse oximeters, newborn hearing screening instruments, and other instruments.

In terms of technology, the Middle East & Africa newborn screening market is categorized into tandem mass spectrometry (TMS), molecular assays, immunoassays and enzymatic assay, pulse oximetry screening technology, and other technologies. The pulse oximetry screening technology segment held 32.7% share of the Middle East & Africa newborn screening market in 2022, amassing US$ 9.46 million. It is projected to garner US$ 15.35 million by 2030 to expand at 6.2% CAGR during 2022-2030.

Based on test type, the Middle East & Africa newborn screening market is categorized into dry blood spot test, hearing screen test, critical congenital heart diseases (CCHD) test, and other test types. The dry blood spot test segment held 51.9% share of Middle East & Africa newborn screening market in 2022, amassing US$ 15.04 million. It is projected to garner US$ 24.58 million by 2030 to expand at 6.3% CAGR during 2022-2030.

By end user, the Middle East & Africa newborn screening market is segmented into hospitals and clinics and diagnostic laboratories. The hospitals and clinics segment held 64.3% share of Middle East & Africa newborn screening market in 2022, amassing US$ 18.62 million. It is projected to garner US$ 30.92 million by 2030 to expand at 6.5% CAGR during 2022-2030.

Based on country, the Middle East & Africa newborn screening market is categorized into the UAE, South Africa, Saudi Arabia, and the Rest of Middle East & Africa. Saudi Arabia held 45.2% share of Middle East & Africa newborn screening market in 2022, amassing US$ 13.08 million. It is projected to garner US$ 21.64 million by 2030 to expand at 6.5% CAGR during 2022-2030.

Key players operating in the Middle East & Africa newborn screening market are Bio-Rad Laboratories Inc, Masimo Corp, Medtronic Plc, PerkinElmer Inc, and Waters Corp, among others.

- In May 2023, Masimo launched Stork, a revolutionary home baby monitoring system. This innovative system offers parents insights into their baby's health data, helping them learn more about and connect better with their baby. The Masimo Stork baby monitor system comprises several components and is available in multiple configurations. Masimo Stork Vitals+, the flagship solution, consists of a boot with a sensor, video camera, and mobile app.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com